BRCA1 and cancer: Primary resistance occurs when cancer cells exhibit intrinsic resistance to therapeutic agents, while secondary (acquired) resistance develops over time, likely due to adaptation to treatment selection pressure [50, 53] For instance, alterations in the BRCA1/2 genes, which are crucial for HRR, are common in OC and can confer initial sensitivity to platinum-based therapies.